哮喘控制状况对血清半胱氨酸蛋白酶抑制剂 C 浓度的影响。

Impact of asthmatic control status on serum cystatin C concentrations.

机构信息

First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.

出版信息

Clin Chem Lab Med. 2012 Aug;50(8):1367-71.

Abstract

BACKGROUND

To determine whether cystatin C accurately reflects renal function in asthma, we investigated serum cystatin C concentrations in a large number of asthmatic patients by adjusting for several confounding factors that might affect serum cystatin C concentrations.

METHODS

A total of 126 asthmatic patients and 126 healthy volunteers, matched for age and gender, were studied.

RESULTS

Serum cystatin C concentrations in symptomatic subjects with asthma were significantly higher than in healthy controls (p < 0.001) and asymptomatic subjects with asthma (p = 0.007), whereas no significant difference was observed between healthy controls and asymptomatic subjects. In asthmatic subjects, serum cystatin C concentrations were not influenced by inhaled corticosteroid (ICS). However, serum cystatin C concentrations were significantly higher in subjects who were regularly treated by oral corticosteroid (OCS) (p = 0.001).

CONCLUSIONS

Serum cystatin C concentrations are elevated in asthmatic patients; particularly while symptomatic and/or taking OCS but not ICS. Serum cystatin C concentrations may not accurately reflect renal function in those patients.

摘要

背景

为了确定胱抑素 C 是否能准确反映哮喘患者的肾功能，我们通过调整可能影响血清胱抑素 C 浓度的几个混杂因素，对大量哮喘患者的血清胱抑素 C 浓度进行了研究。

方法

共纳入 126 例哮喘患者和 126 例年龄和性别相匹配的健康志愿者。

结果

有症状的哮喘患者的血清胱抑素 C 浓度明显高于健康对照组（p < 0.001）和无症状的哮喘患者（p = 0.007），而健康对照组与无症状的哮喘患者之间无显著差异。在哮喘患者中，血清胱抑素 C 浓度不受吸入性皮质类固醇（ICS）的影响。然而，定期接受口服皮质类固醇（OCS）治疗的患者血清胱抑素 C 浓度明显升高（p = 0.001）。